An observational study in Heart Block Complete and Heart Block Second Degree, sponsored by The Hospital for Sick Children. Recruiting at 27 sites in 12 countries. Open to female participants aged 16 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-05-22.
Sponsored by The Hospital for Sick Children · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Heart Block with a site in United States — 5 open to participants now, 5 under way, none of them phase 3. Heart Block · United States.
Among the 13 studies in Heart Block with a site in United States, this one is one of 2 that started in 2020, is one of 7 observational ones, and was the 6th registered.
39 studies on the registry are indexed under Heart Block; 12 are open to participants now.
Browse Heart Block studies →5 of the 13 studies in Heart Block with a site in United States are open now. Recruiting first, the newest first:
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Sites in United States
Ages 18–89
Ascension Health · Sites in United States
Ages 18+
Kansas City Heart Rhythm Research Foundation · Sites in United States
Ages 18+
Peerbridge Health, Inc · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 10 Heart Block studies recruiting now, 7 (70%) set no upper age limit and 1 (10%) stops at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 16 Years to 50 Years · female.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2020.
This study's planned enrollment of 350 is below the median of 765 across 15 observational studies indexed under Heart Block.
Median enrollment 114 across the 6 interventional studies, 350 across the 7 observational. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 13 have an industry lead sponsor. The 10 most frequent:
The Hospital for Sick Children is the lead sponsor of 579 studies on the registry; 81 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
The Hospital for Sick Children has 1 study filed under Heart Block — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Heart Block with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Few studies are specifically designed to address health concerns that are already relevant during pregnancy. The consequence is a lack of evidence on best clinical practice. This includes mothers and their babies when pregnancy is complicated by an abnormally slow heart rate due to maternal antibody-mediated heart disease in the unborn baby (fetus). Since the late seventies, it has been possible to detect and monitor fetal disease by ultrasound images and to treat selected conditions with pharmaceuticals administered via the mother. To this day, physicians need to make decisions about the management of such pregnancies without evidence from prospective clinical trials on drug efficacy and safety. The SLOW HEART REGISTRY is a multi-centered prospective observational study that will address the knowledge gap to guide future management of high-degree immune-mediated heart block to the best of care. The study seeks to establish an international database of the management and outcome of affected fetuses, to be used to publish information on the results of currently available prenatal care and to evaluate the need for additional research.
The SLOW HEART REGISTRY is a multi-centered prospective observational study of fetuses diagnosed with high-degree immune-mediated atrio-ventricular heart block (AVB). The study seeks to establish an international database of the management and outcome of affected fetuses, to be used to publish information on the results of currently available prenatal care and to evaluate the need for additional research.
The study aims are to document the outcome of patients diagnosed prenatally with immune-mediated 2nd or 3rd degree AVB irrespective of the primary choice of prenatal care.
The primary objective will be to determine the rate of transplant-free survival to 1 year of life of fetuses with AVB based on the prenatal management decision:
Secondary objectives will be to determine:
Prevalence of relevant fetal-maternal events and complications (death; IUGR; morbidity) between the study cohorts will also be determined.
All management is decided by the treating center and physicians in accordance to institutional guidelines and clinical findings. Patient enrollment in the SLOW HEART REGISTRY is possible within up to 8 days of the initial management decision.
Participation in this prospective observational cohort study requires site REB approval and an executed legal contract with the primary investigator/SickKids Hospital, Toronto.
Enrollment into the SLOW HEART Registry is possible within maximally 8 days of the fetal heart block diagnosis and a management decision to treat or not to treat. If a mother elects participation in the Registry, her treating physician will continue to provide care in accordance with clinical practice at the site and will decide all therapy including close observation without or with immediate steroid treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Complete AVB (3rd degree) diagnosed ≤ 32+0 weeks with or without hydrops
Drug: Dexamethasone · Other: No Dexamethasone
Incomplete AVB (2nd; 2:1; 2nd-3rd degree) diagnosed ≤ 32+0 weeks with or without hydrops
Drug: Dexamethasone · Other: No Dexamethasone
All management decisions are made by the primary physician and may include: 1) no treatment with dexamethasone or 2) treatment with dexamethasone from the time of enrollment
All management decisions are made by the primary physician and may include: 1) no treatment with dexamethasone or 2) treatment with dexamethasone from the time of enrollment
Freedom from cardiac death ≥1 year of life
Time frame: up to 12 months
Proportion of participants with fetal and neonatal death and their causes/factors
Time frame: 1 month
Proportion of participants with change in prenatal treatment
Time frame: up to 6 months
Proportion of secondarily treated patients (initially untreated group 1 cases)
Time frame: up to 6 months
Proportion of serious pregnancy outcomes (IUFD, IUGR <3rd percentile, delivery <35 weeks)
Time frame: up to 6 months
Proportion of patients/group with progression from incomplete to complete AVB by 1 year
Time frame: Fetal diagnosis to 12 months
Proportion of maternal serious adverse events and outcomes
Time frame: Fetal diagnosis to 12 months
Average gestational age at birth
Time frame: Birth
Average birth weight
Time frame: Birth
Freedom from permanent pacemaker implantation from birth to 1 year of life
Time frame: Birth to 12 months
Prevalence of significant heart failure (HF score, echo, HF treatment) at 1 year of life
Time frame: 12 months
Proportion of children with moderate/severe neuro-developmental delay at 12-18 months
Time frame: 12-18 months
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2020 (actual). Primary completion is estimated for Dec 2027, 95 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Hospital for Sick Children →